330 related articles for article (PubMed ID: 31567375)
1. Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study.
Yao Y; Wang P; Wang XZ; Zhao X; Zhao W; Zhou TN; Zhang L
Chin Med J (Engl); 2019 Oct; 132(19):2292-2299. PubMed ID: 31567375
[TBL] [Abstract][Full Text] [Related]
2. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
[TBL] [Abstract][Full Text] [Related]
3. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Turgeon RD; Koshman SL; Youngson E; Har B; Wilton SB; James MT; Graham MM
JAMA Intern Med; 2020 Mar; 180(3):420-428. PubMed ID: 31930361
[TBL] [Abstract][Full Text] [Related]
4. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.
Wang C; Zheng W; Shaqdan A; Wang C; Qin X; Zhao X; Wang X; Yuan L; Nie S; Liu R
Platelets; 2020; 31(3):337-343. PubMed ID: 31043110
[TBL] [Abstract][Full Text] [Related]
6. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
[TBL] [Abstract][Full Text] [Related]
8. Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome.
Liu L; Liao H; Zhong S; Liu Y; Xiao C
Medicine (Baltimore); 2018 Nov; 97(48):e13381. PubMed ID: 30508934
[TBL] [Abstract][Full Text] [Related]
9. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Nordaby M; Brueckmann M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP
Eur Heart J; 2019 May; 40(19):1553-1562. PubMed ID: 30793734
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Franchi F; Rollini F; Rivas Rios J; Rivas A; Agarwal M; Kureti M; Nagaraju D; Wali M; Shaikh Z; Briceno M; Nawaz A; Moon JY; Been L; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2018 Jun; 137(23):2450-2462. PubMed ID: 29526833
[TBL] [Abstract][Full Text] [Related]
12. Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis.
Wang D; Yang XH; Zhang JD; Li RB; Jia M; Cui XR
BMC Cardiovasc Disord; 2018 Nov; 18(1):217. PubMed ID: 30497387
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices.
Park K; Cho YR; Park JS; Park TH; Kim MH; Kim YD
Circ Cardiovasc Interv; 2019 Oct; 12(10):e008105. PubMed ID: 31554423
[TBL] [Abstract][Full Text] [Related]
14. Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
Galli M; Rollini F; Been L; Zenni MM; Angiolillo DJ; Franchi F
J Thromb Thrombolysis; 2022 Oct; 54(3):461-469. PubMed ID: 36048358
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor Does Not Improve Endothelial Dysfunction in Stable Survivors of Acute Coronary Syndrome.
Lim S; Choo EH; Kim CJ; Choi IJ; Lee KY; Hwang BH; Lee JM; Chung WS; Chang K
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):442-449. PubMed ID: 31035775
[TBL] [Abstract][Full Text] [Related]
16. Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study).
Liu GZ; Zhang S; Sun DH; Shi J; Bo WL; Wang WN; Zhang CY; Wang ZH; Feng W; He MJ; Liu YY; Li S; Zheng LQ; Li Y
Eur J Clin Pharmacol; 2019 Aug; 75(8):1059-1068. PubMed ID: 31081522
[TBL] [Abstract][Full Text] [Related]
17. Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Wang HY; Li Y; Xu XM; Li J; Han YL
Chin Med J (Engl); 2018 Sep; 131(17):2017-2024. PubMed ID: 30127210
[TBL] [Abstract][Full Text] [Related]
18. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.
Caiazzo G; De Rosa S; Torella D; Spaccarotella C; Mongiardo A; Giampà S; Micieli M; Palella E; Gulletta E; Indolfi C
Circ Cardiovasc Interv; 2014 Feb; 7(1):104-12. PubMed ID: 24449597
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry.
Gragnano F; Moscarella E; Calabrò P; Cesaro A; Pafundi PC; Ielasi A; Patti G; Cavallari I; Antonucci E; Cirillo P; Pignatelli P; Palareti G; Pelliccia F; Gaudio C; Sasso FC; Pengo V; Gresele P; Marcucci R;
Intern Emerg Med; 2021 Mar; 16(2):379-387. PubMed ID: 32557093
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: Systematic review and meta-analysis.
Misumida N; Aoi S; Kim SM; Ziada KM; Abdel-Latif A
Cardiovasc Revasc Med; 2018 Sep; 19(6):689-694. PubMed ID: 29452843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
